CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

  • CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira.

  • It will be priced more than 80% lower than the current list price of Humira, which is made by drugmaker Abbvie.

  • CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.